Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises GSK on 23andMe Collaboration and $300M Investment

July 30, 2018

SILICON VALLEYCovington advised GlaxoSmithKline on its multi-year collaboration with and $300 million equity investment in 23andMe.

GSK will become 23andMe’s exclusive collaborator for drug target discovery programs. The collaboration will focus on research and development of innovative new medicines and potential cures using human genetics as the basis for discovery.

The Covington team included Scott Anthony, Peter Laveran-Stiebar, Amy Toro, Anqi Li, David Wildman, and Mengxi Zhu (corporate); Yaron Dori and Dena Feldman (privacy); Wade Ackerman, Lynette Zentgraft, and Christopher Hanson (U.S. regulatory); Grant Castle and Sarah Cowlishaw (EU regulatory); Miranda Cole, James O’Connell, Ross Demain, and Habin Chung (antitrust and competition); Christopher Eppich and Andrew Regan (intellectual property); Peter Flanagan, David Addis, and Molly Doggett (U.S. export control); Richard Mattick (EU export control); and Scott Freling and Nooree Lee (government contracts).

Share this article: